Femasys Inc. Reports Q1 2025 Financial Results with Increased Revenue and Net Loss

Femasys Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $5.9 million, or $0.23 per share, compared to a net loss of $3.6 million, or $0.17 per share, in the same period last year. The company's revenue increased by 25.9% to $341,264, up from $271,140 in the prior year, primarily driven by higher sales of its FemaSeed product. However, total operating expenses surged by 55.9% to $5.7 million, largely due to increased research and development costs, which rose by 67.6% to $2.97 million, and a significant increase in sales and marketing expenses, which jumped 202.4% to $908,567 as the company expanded its commercial team.

In terms of operational metrics, Femasys reported a notable increase in its cash and cash equivalents, which stood at $3.82 million as of March 31, 2025, compared to $3.45 million at the end of the previous fiscal year. The company’s accumulated deficit reached $133.1 million, reflecting ongoing investments in product development and commercialization efforts. The increase in cash was attributed to financing activities, which generated $5.2 million from the sale of common stock under an at-the-market facility, compared to $778,175 in the same quarter last year.

Strategically, Femasys has made significant advancements in its product offerings. The company received CE mark certification for its FemBloc delivery system in March 2025, marking a critical regulatory milestone for its non-surgical permanent birth control solution. Additionally, Femasys announced distribution partnerships for FemBloc in Spain and a collaboration with CNY Fertility to offer FemaSeed, further expanding its market reach. The company is also actively enrolling participants for a pivotal clinical trial aimed at securing U.S. FDA approval for FemBloc.

Looking ahead, Femasys anticipates continued losses as it invests in the commercialization of FemaSeed and the development of FemBloc. The company has indicated that its current cash reserves will not be sufficient to sustain operations for the next twelve months without additional financing. Management has expressed the need to secure further funding to support ongoing operations and product development, emphasizing the uncertainty surrounding its ability to raise capital on favorable terms. The company remains focused on advancing its clinical trials and expanding its product portfolio to address unmet needs in women's health.